Abbvie Inc (ABBV)

$263.17 +1.40 (0.53%)
Market Cap 454.28B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 23.65
Forward PE 18.30
Profit Margin 6.91%
Debt to Equity Ratio -12.03
Volume 1,407,872
Avg Vol 5,157,012
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 84%
Beta 0.29
Analysts Strong Sell
Price Target $277.87

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 15 at 4:37 PM
$SLS Does everyone understand that Oral Aza+VEN IS THE (BAT) - Best Available Treatment for SLS Phase 3 Control Arm Patients - in Second Remission (CR2), ineligible for Transplant ? AND does Everyone Understand Oral az+VEN - FAILED 3 Large Phase 3 Trials Conducted by $ABBV ? including Failing the VIALE-M Trial. • VIALE-M - M for maintenance - AML First Remission Patients CR1 ineligible for T - FAILED • VIALE-T - Post Transplant Maintenance P3 Trial FAILED... Meanwhile we are seeing MIRACULOUS EXTENDED SURVIVAL and • Gps MOS in 2 Phase 2's for AML remission were +2x and 4x better than standard of care. Onureg is SOC for Cr1 - mOS of 24.7 Months - Gps Ph2 in the same exact Setting was 67.6 months... it is not complicated YOU absolutely Know the 3 Drs' treating Actual P3 patients are correct when they stated BAT is dismal/ not durable / extremely poor.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 15 at 4:17 PM
$SLS This is Precisely what a LONG TAIL of Survivorship Looks Like in many Immunotherapy Trials 49 Patients REMAIN --- alive at LEAST 30 months... -- Nearly 40% of these AML Patients In second Remission Unable to withstand Transplant ... - Unheard of / never before seen Miraculous survival - and we know BAT / for Control Patients - is Toxic, does not offer Durable OS, according to 3 Dr's treating actual patients , and BAT FAILED BAT for the REGAL Control ARM FAILED - 3 Large Phase 3 Trials conducted by $ABBV - it is not complicated - its Gps doing what its Done in all 7 Prior Trials, Including 2 PH2's For AML Remission Maintenance. There is NO Survival for CR2 Patients on BAT past 24 months in ANY RECENT TRIAL DATA
1 · Reply
JCJustCharting
JCJustCharting Sep. 15 at 3:52 PM
$ABBV you guys didn’t follow ?
0 · Reply
malibootae
malibootae Sep. 15 at 3:42 PM
$ABBV top of the list of buys after a correction. Looking for $230
0 · Reply
Quantumup
Quantumup Sep. 15 at 12:55 PM
Mizuho⬆️Top Sept Pick $IMMX to $26, reitd Outperform after adding a 2nd pot'l indication for NXC-201 in first-line/1L AL amyloidosis setting w/ pot'l $2B+ peak rev oppy—upcoming catalyst. $PRTA $ABBV JNJ - GMAB SNY BBIO ALNY AZN Here's what Mizuho said in its note to investors: https://x.com/Quantumup1/status/2099844441548681334?s=20
0 · Reply
DidYouReadThis
DidYouReadThis Sep. 14 at 6:01 PM
$OTLK $REGN $NVS $ABBV When the #Bollingerbands #squeeze, the #market is about to?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 14 at 5:35 PM
$OSTX $SLS Very Subtle But Valuable Fact: Gps Ph1/2 MOS 18.4 Months for PR/ROC was longer than the FDA Approved Elahere 16.46 months that $ABBV Paid $10B for, but a SUBTLE distinction is the Patient Setting. GPS Key patients: Measurable Advanced Platinum Resistant Ovarian cancer --- vs $MRNA Melanoma Patients post surgery / semi remission State ... You can read the Conclusions of this GPS Phase 2 Data -- again Extended Survival -Correlated with Immune Response - Like all Gps trials. https://www.reddit.com/media?url=https%3A%2F%2Fpreview.redd.it%2Fgps-keytruda-phase-2-results-for-platinum-resistant-ovarian-v0-p3n52qpjmcph1.png%3Fwidth%3D2810%26format%3Dpng%26auto%3Dwebp%26s%3D24ce0c232be1ebd6148bb30c888a88c0847f1576
0 · Reply
HydrogenH2
HydrogenH2 Sep. 14 at 4:38 PM
$ABBV $JNJ $ABT taking some profits.... Fed's coming wed... and it won't be good news for bulls !!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 14 at 2:08 PM
$SLS This current short rigged $2.3B Market cap isn't even Close to What Gps is worth the moment the Imminent Phase 3 Results are Announced. $MRNA added $40B in a day for a Reason $RVMD added Nearly $30B the day its P3 results were announced. reddit.com/r/sellasLifescience $ABBV and $BMY who own Aza VEN know It ain't BAT Causing the Miraculous Survival.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 14 at 7:52 AM
$SLS $ABBV $BMY BAT for the SLS Control arm Failed 3 Aml remission maintenance trials. what do you think that means? Viale-M Failed in First Remission Viale-T Failed in post Transplant Maintenance Viale C and Verona - Failed
0 · Reply
Latest News on ABBV
AbbVie Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

Sep 15, 2026, 10:00 AM EDT - 3 hours ago

AbbVie Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit

Sep 15, 2026, 8:00 AM EDT - 5 hours ago

Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit

Ipsen considers building production site in U.S., WSJ says

2026-09-11T10:15:37.000Z - 4 days ago

Ipsen considers building production site in U.S., WSJ says

ABBV

AbbVie Declares Quarterly Dividend

Sep 10, 2026, 2:17 PM EDT - 4 days ago

AbbVie Declares Quarterly Dividend

AbbVie's migraine treatment meets late-stage study goal

Sep 10, 2026, 9:04 AM EDT - 5 days ago

AbbVie's migraine treatment meets late-stage study goal

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

2026-09-10T13:00:14.000Z - 5 days ago

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

ABBV

AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

Sep 10, 2026, 8:55 AM EDT - 5 days ago

AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

AbbVie price target raised to $315 from $300 at HSBC

2026-09-10T10:26:53.000Z - 5 days ago

AbbVie price target raised to $315 from $300 at HSBC

ABBV

AbbVie Transcript: Wells Fargo 21st Annual Healthcare Conference

Sep 9, 2026, 10:15 AM EDT - 6 days ago

AbbVie Transcript: Wells Fargo 21st Annual Healthcare Conference

AbbVie price target raised to $282 from $276 at BofA

2026-09-08T12:10:17.000Z - 7 days ago

AbbVie price target raised to $282 from $276 at BofA

ABBV

Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.

Sep 5, 2026, 8:30 AM EDT - 10 days ago

Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.

AIRS LLY NVO

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

2026-09-03T13:25:47.000Z - 12 days ago

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

ABBV

AbbVie's blood cancer drug meets late-stage trial goals

Sep 3, 2026, 9:22 AM EDT - 12 days ago

AbbVie's blood cancer drug meets late-stage trial goals

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

Sep 3, 2026, 9:15 AM EDT - 12 days ago

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

AbbVie completes acquisition of Apogee for $135.11 per share in cash

2026-09-03T12:41:00.000Z - 12 days ago

AbbVie completes acquisition of Apogee for $135.11 per share in cash

ABBV APGE

AbbVie Completes Acquisition of Apogee Therapeutics

Sep 3, 2026, 8:34 AM EDT - 12 days ago

AbbVie Completes Acquisition of Apogee Therapeutics

APGE

AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Sep 3, 2026, 8:05 AM EDT - 12 days ago

AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

AbbVie’s Allergan expands SkinMedica’s portfolio with Barrier Calming Cream

2026-09-01T12:15:42.000Z - 14 days ago

AbbVie’s Allergan expands SkinMedica’s portfolio with Barrier Calming Cream

ABBV

SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings

Sep 1, 2026, 8:05 AM EDT - 14 days ago

SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings

AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference

Aug 31, 2026, 8:00 AM EDT - 15 days ago

AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference

AbbVie submits Skyrizi application to the EMA

2026-08-27T09:21:03.000Z - 19 days ago

AbbVie submits Skyrizi application to the EMA

ABBV

AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Aug 27, 2026, 2:00 AM EDT - 19 days ago

AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Emily Field: Large pharma companies are going to continue looking at biotech

Aug 24, 2026, 10:45 AM EDT - 22 days ago

Emily Field: Large pharma companies are going to continue looking at biotech

IBB MRK MRNA XLV

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

Aug 21, 2026, 7:45 AM EDT - 25 days ago

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

AbbVie price target raised to $303 from $298 at Piper Sandler

2026-08-20T10:55:24.000Z - 26 days ago

AbbVie price target raised to $303 from $298 at Piper Sandler

ABBV

AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support

Aug 18, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support

AbbVie price target raised to $300 from $295 at Wells Fargo

2026-08-17T10:55:57.000Z - 4 weeks ago

AbbVie price target raised to $300 from $295 at Wells Fargo

ABBV

AbbVie upgraded to Outperform from Peer Perform at Wolfe Research

2026-08-17T08:29:38.000Z - 4 weeks ago

AbbVie upgraded to Outperform from Peer Perform at Wolfe Research

ABBV

Expert explains why healthcare is a top-performing sector

Aug 13, 2026, 11:15 PM EDT - 4 weeks ago

Expert explains why healthcare is a top-performing sector

AMGN BIIB GILD JNJ LLY MRK UNH

AbbVie price target raised to $260 from $246 at Evercore ISI

2026-08-10T12:16:02.000Z - 5 weeks ago

AbbVie price target raised to $260 from $246 at Evercore ISI

ABBV

AbbVie upgraded to Buy from Hold at Erste Group

2026-08-05T14:36:14.000Z - 5 weeks ago

AbbVie upgraded to Buy from Hold at Erste Group

ABBV

AbbVie’s Botox Cosmetic sBLA for masseter muscle prominence accepted by FDA

2026-08-04T13:35:25.000Z - 6 weeks ago

AbbVie’s Botox Cosmetic sBLA for masseter muscle prominence accepted by FDA

ABBV

AbbVie’s Allergan Aesthetics receives FDA approval of sBLA for Botox Cosmetic

2026-08-04T12:10:59.000Z - 6 weeks ago

AbbVie’s Allergan Aesthetics receives FDA approval of sBLA for Botox Cosmetic

ABBV

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

Aug 4, 2026, 8:00 AM EDT - 6 weeks ago

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

AbbVie price target raised to $288 from $261 at Guggenheim

2026-08-04T10:52:04.000Z - 6 weeks ago

AbbVie price target raised to $288 from $261 at Guggenheim

ABBV

AbbVie price target raised to $285 from $265 at Cantor Fitzgerald

2026-08-03T12:42:03.000Z - 6 weeks ago

AbbVie price target raised to $285 from $265 at Cantor Fitzgerald

ABBV

AbbVie Earnings Call Transcript: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 6 weeks ago

AbbVie Earnings Call Transcript: Q2 2026

AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 6 weeks ago

AbbVie Earnings release: Q2 2026

AbbVie Quarterly report: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 6 weeks ago

AbbVie Quarterly report: Q2 2026

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

Jul 31, 2026, 8:36 AM EDT - 6 weeks ago

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.

Jul 31, 2026, 8:31 AM EDT - 6 weeks ago

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

Jul 31, 2026, 7:50 AM EDT - 6 weeks ago

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

AbbVie Reports Second-Quarter 2026 Financial Results

Jul 31, 2026, 7:47 AM EDT - 6 weeks ago

AbbVie Reports Second-Quarter 2026 Financial Results

JUVÉDERM® Day Returns to U.S. on August 19

Jul 30, 2026, 8:00 AM EDT - 6 weeks ago

JUVÉDERM® Day Returns to U.S. on August 19

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jul 29, 2026, 3:00 AM EDT - 6 weeks ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

Jul 29, 2026, 3:00 AM EDT - 6 weeks ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jul 23, 2026, 4:00 PM EDT - 7 weeks ago

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

GMAB

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jul 17, 2026, 8:00 AM EDT - 2 months ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Jul 14, 2026, 8:05 AM EDT - 2 months ago

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Buy these quality, low-stress stocks for the summer, says Jefferies

Jul 7, 2026, 11:45 AM EDT - 2 months ago

Buy these quality, low-stress stocks for the summer, says Jefferies

AXP HD LOW MCD NFLX PEP PG

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Jul 6, 2026, 1:45 PM EDT - 2 months ago

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

US House committee opens investigation into Merck, AbbVie China drug trials

Jun 30, 2026, 6:02 AM EDT - 2 months ago

US House committee opens investigation into Merck, AbbVie China drug trials

MRK

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jun 29, 2026, 4:15 PM EDT - 2 months ago

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:10 AM EDT - 2 months ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

Jun 29, 2026, 3:00 AM EDT - 2 months ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 4:50 PM EDT - 2 months ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 2 months ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 2 months ago

AbbVie's $11 Billion Immunology Bet

APGE

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Jun 24, 2026, 8:00 AM EDT - 2 months ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jun 23, 2026, 8:00 AM EDT - 2 months ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 5:00 AM EDT - 2 months ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Jun 23, 2026, 3:00 AM EDT - 2 months ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

EC

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

Jun 22, 2026, 10:30 AM EDT - 2 months ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Transcript: M&A announcement

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Slides: M&A announcement

AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Press release: M&A announcement

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

Jun 22, 2026, 7:06 AM EDT - 2 months ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 2 months ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

Jun 22, 2026, 7:00 AM EDT - 2 months ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

AbbVie would gain an experimental eczema drug by buying biotech: report

Jun 20, 2026, 12:11 PM EDT - 2 months ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 15 at 4:37 PM
$SLS Does everyone understand that Oral Aza+VEN IS THE (BAT) - Best Available Treatment for SLS Phase 3 Control Arm Patients - in Second Remission (CR2), ineligible for Transplant ? AND does Everyone Understand Oral az+VEN - FAILED 3 Large Phase 3 Trials Conducted by $ABBV ? including Failing the VIALE-M Trial. • VIALE-M - M for maintenance - AML First Remission Patients CR1 ineligible for T - FAILED • VIALE-T - Post Transplant Maintenance P3 Trial FAILED... Meanwhile we are seeing MIRACULOUS EXTENDED SURVIVAL and • Gps MOS in 2 Phase 2's for AML remission were +2x and 4x better than standard of care. Onureg is SOC for Cr1 - mOS of 24.7 Months - Gps Ph2 in the same exact Setting was 67.6 months... it is not complicated YOU absolutely Know the 3 Drs' treating Actual P3 patients are correct when they stated BAT is dismal/ not durable / extremely poor.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 15 at 4:17 PM
$SLS This is Precisely what a LONG TAIL of Survivorship Looks Like in many Immunotherapy Trials 49 Patients REMAIN --- alive at LEAST 30 months... -- Nearly 40% of these AML Patients In second Remission Unable to withstand Transplant ... - Unheard of / never before seen Miraculous survival - and we know BAT / for Control Patients - is Toxic, does not offer Durable OS, according to 3 Dr's treating actual patients , and BAT FAILED BAT for the REGAL Control ARM FAILED - 3 Large Phase 3 Trials conducted by $ABBV - it is not complicated - its Gps doing what its Done in all 7 Prior Trials, Including 2 PH2's For AML Remission Maintenance. There is NO Survival for CR2 Patients on BAT past 24 months in ANY RECENT TRIAL DATA
1 · Reply
JCJustCharting
JCJustCharting Sep. 15 at 3:52 PM
$ABBV you guys didn’t follow ?
0 · Reply
malibootae
malibootae Sep. 15 at 3:42 PM
$ABBV top of the list of buys after a correction. Looking for $230
0 · Reply
Quantumup
Quantumup Sep. 15 at 12:55 PM
Mizuho⬆️Top Sept Pick $IMMX to $26, reitd Outperform after adding a 2nd pot'l indication for NXC-201 in first-line/1L AL amyloidosis setting w/ pot'l $2B+ peak rev oppy—upcoming catalyst. $PRTA $ABBV JNJ - GMAB SNY BBIO ALNY AZN Here's what Mizuho said in its note to investors: https://x.com/Quantumup1/status/2099844441548681334?s=20
0 · Reply
DidYouReadThis
DidYouReadThis Sep. 14 at 6:01 PM
$OTLK $REGN $NVS $ABBV When the #Bollingerbands #squeeze, the #market is about to?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 14 at 5:35 PM
$OSTX $SLS Very Subtle But Valuable Fact: Gps Ph1/2 MOS 18.4 Months for PR/ROC was longer than the FDA Approved Elahere 16.46 months that $ABBV Paid $10B for, but a SUBTLE distinction is the Patient Setting. GPS Key patients: Measurable Advanced Platinum Resistant Ovarian cancer --- vs $MRNA Melanoma Patients post surgery / semi remission State ... You can read the Conclusions of this GPS Phase 2 Data -- again Extended Survival -Correlated with Immune Response - Like all Gps trials. https://www.reddit.com/media?url=https%3A%2F%2Fpreview.redd.it%2Fgps-keytruda-phase-2-results-for-platinum-resistant-ovarian-v0-p3n52qpjmcph1.png%3Fwidth%3D2810%26format%3Dpng%26auto%3Dwebp%26s%3D24ce0c232be1ebd6148bb30c888a88c0847f1576
0 · Reply
HydrogenH2
HydrogenH2 Sep. 14 at 4:38 PM
$ABBV $JNJ $ABT taking some profits.... Fed's coming wed... and it won't be good news for bulls !!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 14 at 2:08 PM
$SLS This current short rigged $2.3B Market cap isn't even Close to What Gps is worth the moment the Imminent Phase 3 Results are Announced. $MRNA added $40B in a day for a Reason $RVMD added Nearly $30B the day its P3 results were announced. reddit.com/r/sellasLifescience $ABBV and $BMY who own Aza VEN know It ain't BAT Causing the Miraculous Survival.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 14 at 7:52 AM
$SLS $ABBV $BMY BAT for the SLS Control arm Failed 3 Aml remission maintenance trials. what do you think that means? Viale-M Failed in First Remission Viale-T Failed in post Transplant Maintenance Viale C and Verona - Failed
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 14 at 7:01 AM
$SLS $ABBV $BMY Viale-M, T and C Failed
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 14 at 5:07 AM
$SLS $ABBV $BMY Viale-M T and C Failed
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 13 at 10:58 PM
$SLS The $ABBV $BMY People Know its GPs. This current short rigged $2.3B Market cap isn't even Close to What is Gps is worth the moment the Imminent Phase 3 Results are Announced. $MRNA added $40B in a day for a Reason $RVMD added Nearly $30B the day its P3 results were announced. https://www.reddit.com/r/sellasLifescience/comments/1weo6k2/comment/p9fbhtj/?screen_view_count=1
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 13 at 6:23 PM
$SLS at 60 events the IDMC UNBLINDED ACTUAL PHASE 3 MOS and IMMUNE RESPONSE DATA! Unblinded Actual Median Overall Survival and Immune Response data from the ongoing P3. $ABBV $BMY Own BAT - they all Know Gps is doing what its done in all 7 prior trials, including 2 Phase 2’s for AML REMISSION MAINTENANCE. and Yes BAT Failed 3 large P3’s and 2 for AML MAINTENANCE - Viale-M - Viale-T FAILED.
0 · Reply
Gebinator
Gebinator Sep. 12 at 10:56 PM
$SLS $JNJ $MRK $ABBV September is recognized worldwide as Blood Cancer Awareness Month and Leukemia and Lymphoma Awareness Month, which includes bringing attention to AML. This month, as we reve in the stock price volatility and FOMO frenzy in an anticipation of REGAL '80th event', may we also take a few moments to remember the 80th 'event' is the end of someone's human life? Assuming REGAL success -- I hope the IDMC / FDA / Company would honor the life of this 'event' and all 79 events before, by expediting REGAL FA and the Accelerated Approval process. I'm sure all 80 events would want it that way.
2 · Reply
Scanlz
Scanlz Sep. 12 at 5:04 PM
$ABBV People will always get sick and the need for medicine will never stop.
0 · Reply
JCJustCharting
JCJustCharting Sep. 12 at 4:10 PM
$ABBV anyone wanting another read of this stock, check me out https://x.com/jc_justcharts/status/2098801213592445066?s=46
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 12 at 4:04 AM
$SLS $MRNA $ABBV TRIED 8 Different Oral/IV/subq dosing regimes... all failed.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 12 at 3:50 AM
$SLS $ABBV 19 Month MOS for CR1 First Remission on BAT - is actually just 17.3 months when equalized for the time in treatment vs from Enrollment in REGAL. Any way you look at it 19 or 17 months In CR1 translates to 8 or 9 months MOS in Second Remission CR2 - just like all the doctors treating Regal patients are saying and the same as the Avalon 8.8 month MOS. https://haematologica.org/article/view/14308
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 11:51 PM
$SLS $ABBV We Know from the IDMC Unblinded ACTUAL Phase 3 MOS and Median Follow up Data from the Interim Analysis: • Gps P3 MOS for CR2 will come in > 34 Months - Longer than SOC for CR1. https://www.onclive.com/view/maintenance-galinpepimut-s-appears-effective-and-safe-in-aml-in-second-cr it is not complicated
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 11:45 PM
$SLS $ABBV For the Inch Thick Mile Wide Short Lowlife -- only. Can you explain the implications of the VIALE-M and VIALE-T Phase 3 Trial FAILURES? VIALE-M Phase 3 Combining Oral Az+VEN FAILED for AML FIRST REMISSION MAINTENANCE - BAT for the SLS P3 Control ARM Patients in Second Remission FAILED a Phase 3 For First Remission Maintenance -- Explain....
0 · Reply